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GRAFT PATENCY IN
CORONARYARTERY BYPASS
VERSUS OFF-PUMP
CORONARYARTERY BYPASS
To the Editor:
We read with great interest the arti-
cle by Angelini and associates1 re-
garding effects of coronary artery
bypass grafting with cardiopulmonary
bypass (CABG-CPB) versus off-
pump coronary artery bypass (OP-
CAB) grafting on graft patency from
long-term (7-year) follow-up of 2 ran-
domized controlled trials (Beating
Heart Against Cardioplegic Arrest
Study [BHACAS] 1 and 2). The like-
lihood of graft occlusion was not dif-
ferent between OPCAB (10.6%) and
CABG-CPB (11.0%) groups (odds
ratio, 1.00; 95% confidence interval
[CI], 0.55–1.81; P > .99).1 Mean-
while, our previous meta-analysis2
of randomized controlled trials (not
including the study by Angelini and
collaborators1) demonstrated a statisti-
cally significant increase in venous
graft occlusion (risk ratio [RR],
1.28; 95% CI, 1.06–1.54; P ¼
.0094) and overall graft occlusion
(RR, 1.27; 95% CI, 1.03–1.56; P ¼
.0234) with OPCAB relative to
CABG-CPB in the random-effects
model. We herein updated the meta-
analysis,2 including the study by An-
gelini and colleagues.1
Our comprehensive search identi-
fied 7 studies reporting 3-month
graft patency. Pooled analysis of all
FIGURE 1. Forest plot of venous graft occlusion risk among patients randomized to off-pump coro-
nary artery bypass (OPCAB) grafting versus coronary artery bypass grafting with cardiopulmonary by-
pass (CABG-CPB) in all studies (A) and studies reporting1-year patency (B). IV, Inverse variance; CI,
confidence interval.
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We appreciate the comment and up-
date from Takagi and colleagues. They
previously reported the results of
a meta-analysis of controlled studies,
showing that preoperative statin use
was associated with reduced all-cause
mortality after cardiac surgery.1 At
this time, they added recently published
studies, including ours,2 in the meta-
analysis and showed that preoperative
statin therapy was associated with
a 33% reduction in postoperative mor-
tality (pooled odds ratio, 0.67; 95%
confidence interval, 0.54–0.83; P ¼
.0002), which supports a beneficial ef-
fect of preoperative statin use in pa-
tients undergoing cardiac surgery.
Their pooled analysis included 24,039
patients from 13 controlled studies.
However, the generalizability of their
finding is still not high.
Most patients included in their
pooled analysis underwent coronary ar-
tery bypass surgery. Statins have been
shown to be effective in the prevention
of major cardiac events in coronary ar-
tery disease.3,4 Perhaps most patients
undergoing coronary artery bypass sur-
gery are expected to be taking a statin
before surgery, although routine statin
therapy regardless of low-density lipo-
protein cholesterol level is still contro-
versial. All patients included in our
study had no coronary artery disease.2
Our study has indicated a potential ben-
efit of preoperative statin in patients un-
dergoing cardiac surgery without
coronary artery disease. However, the
study has limitations of observational
studies. A randomized controlled study
is necessary to confirm the finding.
To generalize the beneficial effect of
preoperative statin use in patients un-
dergoing cardiac surgery, further in-
vestigations are necessary in patients
without coronary artery disease or
those without hypercholesterolemia.
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